Beg Sabina, Ragunath Krish
Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospital, Queens Medical Centre, Derby Road, Nottingham NG7 2UH, UK.
Best Pract Res Clin Gastroenterol. 2015 Aug;29(4):627-38. doi: 10.1016/j.bpg.2015.05.008. Epub 2015 Jun 4.
Gastrointestinal malignancy accounts for approximately a fifth of all cancer deaths in the United Kingdom. By the time patients are symptomatic, lesions are often advanced, with limited treatment options available. The development of effective endoscopic therapies means that neoplastic lesions can now be treated with improved patient outcomes. This has led to a paradigm shift, whereby the aim of digestive endoscopy is to identify premalignant conditions or early neoplastic change, in order to make an impact on their natural history. This has necessitated an improvement in imaging techniques in order to identify subtle mucosal changes that may harbour precancerous cells. At present there is an array of available imaging modalities, each with implications on cost, training and lesion detection. Here we describe the scientific rationale behind the major commercially available techniques as well as offering a glimpse at possible future directions.
在英国,胃肠道恶性肿瘤约占所有癌症死亡人数的五分之一。当患者出现症状时,病变往往已处于晚期,可供选择的治疗方案有限。有效的内镜治疗方法的发展意味着现在可以通过改善患者预后的方式来治疗肿瘤性病变。这导致了一种范式转变,即消化内镜检查的目的是识别癌前病变或早期肿瘤变化,以便对其自然病程产生影响。这就需要改进成像技术,以识别可能含有癌前细胞的细微黏膜变化。目前有一系列可用的成像模式,每种模式在成本、培训和病变检测方面都有影响。在这里,我们描述了主要商用技术背后的科学原理,并对未来可能的发展方向进行了展望。